• Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Oct 21, 2022
Deals

Oct. 21 Quick Takes: Newly spun out Biohaven prices upsized follow-on

Plus Singapore’s AUM merging with SPAC, and updates from Angelini and DeepUll
Read More
BioCentury | Apr 7, 2021
Distillery Therapeutics

eIF4E identified as target in obesity, fatty liver disease

DISEASE CATEGORY: Endocrine/metabolic
INDICATION: Obesity; liver disease Reducing levels of eIF4E or lowering the RNA cap-binding protein’s activity by blocking its phosphorylation could
Read More
BioCentury | Aug 8, 2020
Translation in Brief

Cocrystal’s COVID-19 antivirals; plus a portable breast cancer diagnostic, Tarveda mini-drug conjugate for solid tumors, and more

BioCentury’s roundup of preclinical news
Read More
BioCentury | Jan 9, 2020
Product Development

Pfizer dips into translational regulation for cancer with eFFECTOR deal

Pfizer’s deal with eFFECTOR points to translational regulators as an emerging target source
Read More
BioCentury | May 24, 2019
Emerging Company Profile

Anima opens new target space in translational control

How Anima is leveraging its translational control platform to pursue new targets, small molecules and big pharma deals
Read More
BioCentury | Feb 2, 2018
Clinical News

Effector reports Phase I/II data for eFT508 in hematological malignancies

Read More
BioCentury | Dec 9, 2017
Product Development

Multimodal meeting

ASH 2017 by the numbers: cell and gene therapies making inroads
Read More
BioCentury | Nov 3, 2017
Clinical News

Effector begins Phase II trial of eFT508 plus Bavencio

Read More
BioCentury | Aug 9, 2017
Distillery Therapeutics

Neurology

Read More
BioCentury | Jul 29, 2017
Finance

Potentiator potential

Why Pfizer Venture Investments led Effector's $38.6M series C
Read More
Items per page:
1 - 10 of 21